MCID: DXR001
MIFTS: 34

Doxorubicin Induced Cardiomyopathy malady

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

About this section

Aliases & Descriptions for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 45

Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

About this section
MalaCards based summary: Doxorubicin Induced Cardiomyopathy is related to breast cancer and lymphoma. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways are Physiological and Pathological Hypertrophy of the Heart and Syndecan-1-mediated signaling events. Affiliated tissues include breast, brain and lung, and related mouse phenotypes are respiratory system and no phenotypic analysis.

Related Diseases for Doxorubicin Induced Cardiomyopathy

About this section

Graphical network of the top 20 diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to doxorubicin induced cardiomyopathy

Symptoms for Doxorubicin Induced Cardiomyopathy

About this section

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

About this section

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 8)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Doxorubicinapproved, investigationalPhase 2, Phase 3158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
2
DoxilApproved June 1999Phase 2, Phase 3158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
3Antibiotics, AntitubercularPhase 2, Phase 35971
4Topoisomerase InhibitorsPhase 2, Phase 34081
5Anti-Bacterial AgentsPhase 2, Phase 39140
6
Cyclophosphamideapproved, investigationalPhase 2264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
7
PaclitaxelapprovedPhase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
8Albumin-Bound PaclitaxelPhase 22621

Interventional clinical trials:

idNameStatusNCT IDPhase
1Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer PatientsRecruitingNCT02078388Phase 2, Phase 3
299mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerNot yet recruitingNCT02677714Phase 2

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

About this section

Anatomical Context for Doxorubicin Induced Cardiomyopathy

About this section

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

33
Breast, Brain, Lung, T cells, Bone, Pituitary, Endothelial

Animal Models for Doxorubicin Induced Cardiomyopathy or affiliated genes

About this section

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy:

38 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.7EGFR, EPOR, GATA4, MAPK14, MET
2MP:00030128.5CNR1, EGFR, EPOR, GATA4, HGF, MET
3MP:00053708.4EGFR, EPOR, GATA4, HGF, MAPK14, MET
4MP:00053818.2CNR1, ECE1, EGFR, EPHB2, GATA4, MET
5MP:00053798.2ECE1, EGFR, EPHB2, GATA4, MAPK14, MET
6MP:00053697.9DES, ECE1, EGFR, GATA4, MAPK14, MET
7MP:00107717.9CNR1, CSF3, ECE1, EGFR, GATA4, MAPK14
8MP:00053807.8ECE1, EGFR, EPOR, GATA4, HGF, MAPK14
9MP:00028737.7CNR1, ECE1, EGFR, EPOR, GATA4, MAPK14
10MP:00036317.3CNR1, ECE1, EGFR, EPHB2, EPOR, GATA4
11MP:00053847.2CNR1, DES, EGFR, EPHB2, EPOR, GATA4
12MP:00053767.2CNR1, DES, ECE1, EGFR, EPOR, GATA4
13MP:00053977.1CSF3, ECE1, EGFR, EPOR, GATA4, HGF
14MP:00053856.9DES, ECE1, EGFR, EPOR, GATA4, HGF
15MP:00053786.7CNR1, ECE1, EGFR, EPHB2, EPOR, GATA4
16MP:00107686.4CNR1, DES, ECE1, EGFR, EPHB2, EPOR

Publications for Doxorubicin Induced Cardiomyopathy

About this section

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50)    (show all 125)
idTitleAuthorsYear
1
Kidney transplantation in an adult patient with VACTERL association. (26106170)
2015
2
Type A aortic dissection in fibromuscular dysplasia. (25744128)
2015
3
Outcomes of Aortic Valve-Sparing Operations in Marfan Syndrome. (26403341)
2015
4
Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). (24720433)
2014
5
Role of human papilloma virus-16 in the pathogenesis of oral lichen planus - an immunohistochemical study. (25256345)
2014
6
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. (24382738)
2014
7
Differential effects of common variants in SCN2A on general cognitive ability, brain physiology, and messenger RNA expression in schizophrenia cases and control individuals. (24718902)
2014
8
Nicotinamide N-methyltransferase enhances the capacity of tumorigenesis associated with the promotion of cell cycle progression in human colorectal cancer cells. (25201588)
2014
9
Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability. (25381298)
2014
10
Pediatric insomnia: clinical, diagnosis, and treatment. (24343539)
2014
11
TRPV4 partially participates in proliferation of human brain capillary endothelial cells. (23333822)
2013
12
Neurology and the bladder: how to assess and manage neurogenic bladder dysfunction. With particular references to neural control of micturition. (23524597)
2013
13
Is chronic fatigue syndrome in older patients a different disease? -- a clinical cohort study. (23397955)
2013
14
Cataract surgery in patients with corneal disease. (23197265)
2013
15
Neurobehavioral phenotype observed in KBG syndrome caused by ANKRD11 mutations. (23184435)
2013
16
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. (23639612)
2013
17
The differential diagnosis of syncope: a guide for emergency department advanced practice nurses. (23111310)
2012
18
miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. (21868754)
2011
19
ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. (20821239)
2011
20
Monkeypox disease transmission in an experimental setting: prairie dog animal model. (22164263)
2011
21
Neuron-restrictive silencer factor causes epigenetic silencing of Kv4.3 gene after peripheral nerve injury. (20006971)
2010
22
Occurrence of Tako-Tsubo cardiomyopathy and chronobiological variation. (20117468)
2010
23
Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues. (19885561)
2009
24
Seroreactivity against PTEN-induced putative kinase 1 (PINK1) in Turkish patients with BehAset's disease. (19796537)
2009
25
Tyrosine phosphatase PTPalpha regulates focal adhesion remodeling through Rac1 activation. (18216165)
2008
26
Localization, characterization and function of pituitary adenylate cyclase-activating polypeptide during brain development. (17719696)
2007
27
Alcohol dehydrogenase 2 genotype and allelic variants are not associated with the risk for essential tremor. (17762315)
2007
28
Current understanding of pathogenesis of Graves ophthalmopathy]. (17154091)
2006
29
Reflux in esophageal atresia, tracheoesophageal cleft, and esophagocoloplasty: Bianchi's procedure as an alternative approach. (15852275)
2005
30
Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. (15010892)
2004
31
Sinus and paced P wave duration and dispersion as predictors of atrial fibrillation after pacemaker implantation in patients with isolated sick sinus syndrome. (15125716)
2004
32
Human T-cell leukemia virus type I and adult T-cell leukemia. (12910250)
2003
33
Dorz1, a novel gene expressed in differentiating cerebellar granule neurons, is down-regulated in Zic1-deficient mouse. (14667578)
2003
34
Hemin induces neuroglobin expression in neural cells. (12239161)
2002
35
Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8 cM interval. (12476321)
2002
36
Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. (11705862)
2001
37
RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs. (11124835)
2001
38
Functional and mobility impairments associated with Paget's disease of bone. (7730531)
1995
39
Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer. (9815938)
1995
40
Posterior scleritis as a fundus mass. (8183510)
1994
41
A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis. (7890905)
1994
42
Bronchogenic cyst associated with left lower lobe bronchiectasis. (8255638)
1993
43
Induction and inhibition of cytochrome P-450-dependent monooxygenases in hamster tissues by ethanol. (8378940)
1993
44
Disturbances in volume regulating hormone system--a key to the pathogenesis of hypertension in obstructive sleep apnea syndrome? (1650945)
1991
45
Expression of the pS2 gene in human gastric cancer cells derived from poorly differentiated adenocarcinoma. (2311759)
1990
46
Medullary cancer of the breast revisited. (2085673)
1990
47
Conserved structures among the nucleocapsid proteins of the paramyxoviridae: complete nucleotide sequence of human parainfluenza virus type 3 NP mRNA. (3012866)
1986
48
Treatment of superior limbic keratoconjunctivitis by thermocauterization of the superior bulbar conjunctiva. (3951822)
1986
49
Magnetic resonance imaging of transfusional hemosiderosis complicating thalassemia major. (6695078)
1984
50
Liver inclusions in erythropoietic protoporphyria. (1122921)
1975

Variations for Doxorubicin Induced Cardiomyopathy

About this section

Expression for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section
Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 24)
idSuper pathwaysScoreTop Affiliating Genes
19.7GATA4, MAPK14
29.7HGF, MET
39.6EGFR, EPOR
49.5EGFR, MET
59.4GATA4, HGF, MET
69.2EGFR, HGF, MET
79.2EGFR, HGF, MET
89.2EGFR, HGF, MET
99.2EGFR, HGF, MET
108.8CSF3, HGF, MET
11
Show member pathways
8.8EGFR, EPOR, GATA4, MAPK14
128.7EGFR, HGF, MAPK14, MET
13
Show member pathways
8.4EGFR, EPHB2, EPOR, HGF, MET
14
Show member pathways
8.4CNR1, EGFR, HGF, MAPK14, MET
15
Show member pathways
8.3EGFR, EPHB2, HGF, MAPK14, MET
16
Show member pathways
8.2EGFR, EPHB2, EPOR, MAPK14, MET
178.0CSF3, EGFR, EPOR, HGF, MET
18
Show member pathways
7.9EGFR, EPHB2, EPOR, HGF, MAPK14, MET
19
Show member pathways
7.9EGFR, EPHB2, EPOR, HGF, MAPK14, MET
20
Show member pathways
7.9EGFR, EPHB2, EPOR, HGF, MAPK14, MET
21
Show member pathways
7.6EGFR, EPHB2, EPOR, GATA4, HGF, MAPK14
22
Show member pathways
7.1CSF3, EGFR, EPHB2, EPOR, HGF, MAPK14
23
Show member pathways
6.7CSF3, DES, EGFR, EPHB2, EPOR, HGF
24
Show member pathways
6.4CSF3, ECE1, EGFR, EPHB2, EPOR, HGF

GO Terms for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell morphogenesisGO:000090210.1HGF, MAPK14
2positive chemotaxisGO:00509189.9HGF, MET
3protein phosphorylationGO:00064688.6EGFR, EPHB2, MAPK14, MET
4positive regulation of transcription from RNA polymerase II promoterGO:00459448.4EGFR, GATA4, MAPK14, MET

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein tyrosine kinase activityGO:00047139.2EGFR, EPHB2, MET

Sources for Doxorubicin Induced Cardiomyopathy

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet